Question 1

What are aminosalicylates and how do they treat IBD?

Accepted Answer

Aminosalicylates, such as sulfasalazine, are first-line agents containing 5-aminosalicylic acid that block prostaglandin and leukotriene production to prevent inflammation recurrence. They suppress proinflammatory cytokines and interfere with arachidonic acid metabolism, making them effective for both Crohn's disease and ulcerative colitis. These drugs can be administered orally, rectally, or intravenously for targeted treatment throughout the digestive tract.

Question 2

When are corticosteroids used in IBD management?

Accepted Answer

Corticosteroids like prednisone are potent anti-inflammatory drugs administered at high doses specifically for acute IBD flare-ups when aminosalicylate compounds prove insufficient. They can be taken orally, rectally, or intravenously based on individual requirements. However, corticosteroids lack efficacy in remission maintenance and are not used for long-term disease control.

Question 3

How do immunomodulators help maintain IBD remission?

Accepted Answer

Immunomodulators like azathioprine inhibit T-cell function and limit gut inflammation by inducing T-cell apoptosis. These agents demonstrate long-term efficacy, effectively reducing inflammation and diminishing the need for corticosteroids, hospitalization, and surgery. Although they have delayed onset and are unsuitable for acute flare-ups, immunomodulators can maintain remission for years.

Question 4

What role do antibiotics play in treating Crohn's disease complications?

Accepted Answer

Antibiotics like metronidazole and ciprofloxacin alter gut microbiota, reduce bacterial overgrowth, and exhibit anti-inflammatory effects. They are particularly useful in managing Crohn's disease complications such as infections, fistulas, or abscesses. By decreasing harmful bacteria and modifying the microbiome, antibiotics help control localized inflammatory complications.

Question 5

How do biologic therapies target IBD inflammation?

Accepted Answer

Biologic therapies constitute an advanced treatment category targeting specific inflammation-related proteins. Anti-TNF medications inhibit TNF-α-associated inflammatory responses, integrin blockers impede white blood cell infiltration into the GI tract, and interleukin blockers like ustekinumab target interleukin-12 and interleukin-23. These targeted approaches prevent chronic inflammation and tissue damage more precisely than traditional medications.

Question 6

What are the primary management goals when IBD is diagnosed?

Accepted Answer

Upon diagnosis, managing inflammatory bowel disease involves resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel includes medications to reduce inflammation and promote healing. Correcting malnutrition often requires dietary adjustments and nutritional supplements, while symptomatic relief aims to ease pain, diarrhea, and other discomforts associated with IBD.

Question 7

Why is regular monitoring important during IBD pharmacologic treatment?

Accepted Answer

Different pharmacologic therapies have varying considerations and potential side effects requiring close oversight. Regular monitoring through blood tests and follow-up with a gastroenterologist or IBD specialist is crucial for optimizing treatment effectiveness and preventing complications. This collaborative approach ensures medications remain appropriate and adjusted as needed throughout the disease course.

Inflammatory Bowel Disease IV: Pharmacological Management

Browse More Videos